First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade III well-differentiated neuroendocrine tumors (NET G3).

e16709 Background: The 2019 World Health Organization (WHO) classification of neuroendocrine neoplasia (NEN) introduced the new category of well-differentiated NEN with Ki67 proliferation index ≥20% (NET G3). Fluoropyrimidine-based regimens with oxaliplatin (FOLFOX/XELOX) were a treatment option in neuroendocrine carcinomas with low Ki67. However, FOLFOX/XELOX efficacy in this newly defined NET G3 category is unknown. Objective of this study was...